DE60327225D1 - Aripiprazol-komplex-formulierung und verfahren - Google Patents

Aripiprazol-komplex-formulierung und verfahren

Info

Publication number: DE60327225D1
Authority: DE; Germany
Prior art keywords: aripiprazol; complex formulation; formulation; complex; aripiprazol complex
Prior art date: 2002-08-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60327225T

Other languages

English (en)

Inventor

Manoj Nerurkar

Vijay Naringrekar

Mark Dominick

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-20

Filing date

2003-08-14

Publication date

2009-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60327225(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-14 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2009-05-28 Application granted granted Critical

2009-05-28 Publication of DE60327225D1 publication Critical patent/DE60327225D1/de

2023-08-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Inorganic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE60327225T 2002-08-20 2003-08-14 Aripiprazol-komplex-formulierung und verfahren Expired - Lifetime DE60327225D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40471302P	2002-08-20	2002-08-20
PCT/US2003/025573 WO2004017897A2 (en)	2002-08-20	2003-08-14	Aripiprazole complex formulation and method

Publications (1)

Publication Number	Publication Date
DE60327225D1 true DE60327225D1 (de)	2009-05-28

Family

ID=31946748

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60327225T Expired - Lifetime DE60327225D1 (de)	2002-08-20	2003-08-14	Aripiprazol-komplex-formulierung und verfahren

Country Status (32)

Country	Link
US (8)	US7115587B2 (de)
EP (1)	EP1542668B1 (de)
JP (1)	JP4729306B2 (de)
KR (1)	KR101043866B1 (de)
CN (1)	CN100335047C (de)
AR (2)	AR040887A1 (de)
AT (1)	ATE428423T1 (de)
AU (1)	AU2003269965B2 (de)
BR (1)	BR0313602A (de)
CA (1)	CA2495864C (de)
CY (1)	CY1110331T1 (de)
DE (1)	DE60327225D1 (de)
DK (1)	DK1542668T3 (de)
ES (1)	ES2322953T3 (de)
GE (1)	GEP20063996B (de)
HR (1)	HRP20050149B1 (de)
IL (1)	IL166623A (de)
IS (1)	IS2878B (de)
MX (1)	MXPA05001865A (de)
MY (1)	MY140793A (de)
NO (1)	NO333458B1 (de)
NZ (1)	NZ537995A (de)
PE (1)	PE20040895A1 (de)
PL (1)	PL212428B1 (de)
PT (1)	PT1542668E (de)
RS (1)	RS51903B (de)
RU (1)	RU2342931C2 (de)
SI (1)	SI1542668T1 (de)
TW (1)	TWI307626B (de)
UA (1)	UA79984C2 (de)
WO (1)	WO2004017897A2 (de)
ZA (1)	ZA200501064B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040170705A1 (en) *	2001-03-08	2004-09-02	Dusan Miljkovic	Compositions and methods for non-insulin glucose uptake
DK1542668T3 (da) *	2002-08-20	2009-07-20	Bristol Myers Squibb Co	Formulering af aripiprazolkompleks og fremgangsmåde
SI1675573T2 (sl)	2003-10-23	2012-08-31	Otsuka Pharma Co Ltd	Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproĹˇÄŤanjem in postopek
PL1613598T3 (pl) *	2003-12-16	2012-03-30	Teva Pharma	Sposób wytwarzania krystalicznych form aripiprazolu
US7714129B2 (en)	2003-12-16	2010-05-11	Teva Pharmaceutical Industries Ltd.	Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
DE112006000921T5 (de) *	2005-04-13	2008-05-08	Elan Pharma International Ltd., Athlone	Nanopartikuläre Zusammensetzungen zur kontrollierten Freisetzung, die Prostaglandin-Derivate umfassen
ATE459341T1 (de) *	2005-06-03	2010-03-15	Elan Pharma Int Ltd	Nanoteilchenförmige imatinib-mesylat- formulierungen
EP1903039A4 (de) *	2005-06-13	2010-09-22	Takeda Pharmaceutical	Injektion
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
US8022054B2 (en)	2005-11-28	2011-09-20	Marinus Pharmaceuticals	Liquid ganaxolone formulations and methods for the making and use thereof
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
CN101322709B (zh) *	2007-06-12	2011-03-02	成都康弘药业集团股份有限公司	一种含有阿立哌唑的药物组合物及其制备方法
ES2661037T3 (es) *	2007-07-31	2018-03-27	Otsuka Pharmaceutical Co., Ltd.	Procedimientos para producir una suspensión de aripiprazol y una formulación liofilizada
US8501740B2 (en) *	2007-10-09	2013-08-06	Board Of Regents, The University Of Texas System	Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
MX2010009848A (es) *	2008-03-21	2010-09-30	Elan Pharma Int Ltd	Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
CA2766033C (en)	2009-06-25	2016-09-20	Alkermes, Inc.	Prodrugs of nh-acidic compounds
SMT201700430T1 (it)	2009-06-25	2018-01-11	Alkermes Pharma Ireland Ltd	Composti eterociclici per il trattamento di disturbi neurologici e psicologici
WO2011023796A1 (en)	2009-08-31	2011-03-03	Abbott Healthcare Products B.V.	Bifeprunox for treating addiction
KR101125210B1 (ko) *	2009-09-11	2012-03-19	주식회사 대웅제약	아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) *	2009-12-10	2011-06-16	Molecular Imprints, Inc.	Imprint lithography template
EP2585066B1 (de)	2010-06-24	2018-09-26	Alkermes Pharma Ireland Limited	Prodrugs aus nh-säureverbindungen: ester-, carbonat-, carbamat- und phosphonat-derivate
US8383663B2 (en) *	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
RU2627469C2 (ru)	2011-03-18	2017-08-08	Алкермес Фарма Айэленд Лимитед	Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
ES2715562T3 (es)	2011-12-15	2019-06-04	Alkermes Pharma Ireland Ltd	Profármacos de compuestos de amina secundaria
TW201332572A (zh) *	2011-12-28	2013-08-16	Otsuka Pharma Co Ltd	具有經取代的β－環糊精之藥物製劑
ES2774901T3 (es)	2012-02-15	2020-07-23	Cydex Pharmaceuticals Inc	Proceso para la fabricación de derivados de ciclodextrina
ES2950418T3 (es)	2012-03-19	2023-10-09	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden alcohol bencílico
AU2013235523B9 (en)	2012-03-19	2018-01-04	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising glycerol esters
ES2765036T3 (es)	2012-03-19	2020-06-05	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden esteres de ácidos grasos
JOP20200109A1 (ar) *	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
KR101571670B1 (ko)	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
NZ730571A (en)	2012-09-19	2018-12-21	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions having improved storage stability
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
GR1008186B (el)	2013-04-22	2014-05-08	"Φαρματεν Α.Β.Ε.Ε.",	Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) *	2013-07-10	2017-09-27	共和薬品工業株式会社	アリピプラゾール含有水性液剤
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) *	2013-09-26	2015-03-26	General Electric Company	Method of manufacturing a component and thermal management process
CA3195252A1 (en)	2013-12-24	2015-07-02	Durect Corporation	Uses of oxygenated cholesterol sulfates (ocs)
GR1008442B (el)	2014-01-16	2015-03-05	"Φαρματεν Α.Β.Ε.Ε.",	Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
MA39495A (fr)	2014-03-20	2015-09-24	Alkermes Pharma Ireland Ltd	Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
CN105078910B (zh) *	2015-09-22	2018-05-22	成都欣捷高新技术开发有限公司	一种含有依匹哌唑的冻干口服制剂及其制备方法
EA036155B1 (ru)	2015-10-16	2020-10-06	Маринус Фармасьютикалс, Инк.	Инъекционные составы нейростероида, содержащие наночастицы
CN105616344A (zh) *	2016-01-06	2016-06-01	万全万特制药江苏有限公司	阿立哌唑注射液及其制备方法
SI3494125T1 (sl) *	2016-08-02	2022-10-28	Virginia Commonwealth University	Sestavki, ki vsebujejo 5-holesten-3, 25-diol, 3-sulfat(25HC3S) ali njegovo farmacevtsko sprejemljivo sol in vsaj en cikličen oligosaharid
CN119112906A (zh)	2016-08-11	2024-12-13	奥维德医疗公司	用于治疗癫痫性紊乱的方法和组合物
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
WO2018091668A1 (en)	2016-11-18	2018-05-24	Aicuris Anti-Infective Cures Gmbh	Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
WO2019102992A1 (ja) *	2017-11-21	2019-05-31	積水化学工業株式会社	皮膚外用剤
EP3761983A1 (de)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Dosierstrategie für aripiprazol
WO2020118142A1 (en)	2018-12-07	2020-06-11	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2021026124A1 (en)	2019-08-05	2021-02-11	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in treatment of status epilepticus
IL293525A (en)	2019-12-06	2022-08-01	Marinus Pharmaceuticals Inc	Ganaxolone for use in treating tuberous sclerosis complex
CA3198795A1 (en) *	2020-11-18	2022-05-27	Jeffrey Becker	Complexing agent salt formulations of pharmaceutical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6407079B1 (en)	1985-07-03	2002-06-18	Janssen Pharmaceutica N.V.	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en)	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2893175B2 (ja) *	1988-10-31	1999-05-17	大塚製薬株式会社	カルボスチリル誘導体
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1263831B (it)	1993-01-29	1996-09-04	Paolo Chiesi	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) *	1993-12-09	1995-06-27	Hisamitsu Pharmaceut Co Inc	シクロデキストリンの複合組成物及び複合化法
US5646131A (en)	1994-02-22	1997-07-08	The Arab Company For Drug Industries And Medical Applicances (Acdima)	Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it)	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk)	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) *	1996-05-08	2007-11-28	大塚製薬株式会社	抗不安薬
JPH10194996A (ja)	1996-12-25	1998-07-28	Janssen Pharmaceut Nv	アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en)	1997-06-21	1997-08-27	Pfizer Ltd	Pharmaceutical formulations
GB9915231D0 (en)	1999-06-29	1999-09-01	Pfizer Ltd	Pharmaceutical complex
CA2311734C (en)	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
MY129350A (en) *	2001-04-25	2007-03-30	Bristol Myers Squibb Co	Aripiprazole oral solution
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) *	2002-02-01	2002-02-01	Axon Biochemicals Bv	Thio-carbostyril derivative
DK1542668T3 (da) *	2002-08-20	2009-07-20	Bristol Myers Squibb Co	Formulering af aripiprazolkompleks og fremgangsmåde
EP1562546A1 (de)	2002-10-25	2005-08-17	Pfizer Products Inc.	Depotformulierungen arylheterozyklischer wirkstoffen in form von suspensionen

2003
- 2003-08-14 DK DK03751859T patent/DK1542668T3/da active
- 2003-08-14 GE GEAP8703A patent/GEP20063996B/en unknown
- 2003-08-14 SI SI200331586T patent/SI1542668T1/sl unknown
- 2003-08-14 WO PCT/US2003/025573 patent/WO2004017897A2/en active Application Filing
- 2003-08-14 US US10/642,366 patent/US7115587B2/en not_active Expired - Lifetime
- 2003-08-14 DE DE60327225T patent/DE60327225D1/de not_active Expired - Lifetime
- 2003-08-14 MX MXPA05001865A patent/MXPA05001865A/es active IP Right Grant
- 2003-08-14 TW TW092122407A patent/TWI307626B/zh not_active IP Right Cessation
- 2003-08-14 ES ES03751859T patent/ES2322953T3/es not_active Expired - Lifetime
- 2003-08-14 KR KR1020057002789A patent/KR101043866B1/ko not_active Expired - Fee Related
- 2003-08-14 AT AT03751859T patent/ATE428423T1/de active
- 2003-08-14 CA CA2495864A patent/CA2495864C/en not_active Expired - Fee Related
- 2003-08-14 JP JP2004531017A patent/JP4729306B2/ja not_active Expired - Fee Related
- 2003-08-14 NZ NZ537995A patent/NZ537995A/en not_active IP Right Cessation
- 2003-08-14 EP EP03751859A patent/EP1542668B1/de not_active Expired - Lifetime
- 2003-08-14 RS YU20050118A patent/RS51903B/sr unknown
- 2003-08-14 BR BR0313602-7A patent/BR0313602A/pt not_active Application Discontinuation
- 2003-08-14 PL PL374798A patent/PL212428B1/pl unknown
- 2003-08-14 PT PT03751859T patent/PT1542668E/pt unknown
- 2003-08-14 AU AU2003269965A patent/AU2003269965B2/en not_active Ceased
- 2003-08-14 CN CNB038195534A patent/CN100335047C/zh not_active Expired - Fee Related
- 2003-08-14 UA UAA200502492A patent/UA79984C2/uk unknown
- 2003-08-14 RU RU2005107471/15A patent/RU2342931C2/ru not_active IP Right Cessation
- 2003-08-15 MY MYPI20033103A patent/MY140793A/en unknown
- 2003-08-19 AR AR20030102990A patent/AR040887A1/es not_active Application Discontinuation
- 2003-08-20 PE PE2003000843A patent/PE20040895A1/es not_active Application Discontinuation
2005
- 2005-02-01 IL IL166623A patent/IL166623A/en active IP Right Grant
- 2005-02-04 ZA ZA200501064A patent/ZA200501064B/xx unknown
- 2005-02-08 NO NO20050661A patent/NO333458B1/no not_active IP Right Cessation
- 2005-02-16 HR HRP20050149AA patent/HRP20050149B1/hr not_active IP Right Cessation
- 2005-02-18 IS IS7701A patent/IS2878B/is unknown
2006
- 2006-06-14 US US11/452,782 patent/US7550445B2/en not_active Expired - Fee Related
2009
- 2009-04-02 US US12/417,067 patent/US20090186903A1/en not_active Abandoned
- 2009-07-07 CY CY20091100712T patent/CY1110331T1/el unknown
2011
- 2011-03-11 US US13/046,124 patent/US20110160224A1/en not_active Abandoned
- 2011-11-03 US US13/288,077 patent/US20120053145A1/en not_active Abandoned
2012
- 2012-10-22 US US13/656,785 patent/US20130045981A1/en not_active Abandoned
2013
- 2013-04-29 US US13/872,517 patent/US8999952B2/en not_active Expired - Fee Related
2015
- 2015-03-03 US US14/636,283 patent/US20150328335A1/en not_active Abandoned
- 2015-09-28 AR ARP150103114A patent/AR102101A2/es unknown

Also Published As

Publication number	Publication date
US20140235574A1 (en)	2014-08-21
WO2004017897A3 (en)	2004-12-02
PL212428B1 (pl)	2012-09-28
US20150328335A1 (en)	2015-11-19
DK1542668T3 (da)	2009-07-20
RS20050118A (en)	2007-06-04
SI1542668T1 (sl)	2009-08-31
MY140793A (en)	2010-01-15
ES2322953T3 (es)	2009-07-02
IL166623A (en)	2011-07-31
PL374798A1 (en)	2005-10-31
TWI307626B (en)	2009-03-21
IL166623A0 (en)	2006-01-15
HRP20050149B1 (hr)	2014-09-12
AR102101A2 (es)	2017-02-01
BR0313602A (pt)	2005-06-21
EP1542668A2 (de)	2005-06-22
EP1542668B1 (de)	2009-04-15
IS7701A (is)	2005-02-18
PT1542668E (pt)	2009-06-09
GEP20063996B (en)	2006-12-11
US20040077594A1 (en)	2004-04-22
US8999952B2 (en)	2015-04-07
CA2495864A1 (en)	2004-03-04
UA79984C2 (en)	2007-08-10
KR101043866B1 (ko)	2011-06-22
HRP20050149A2 (en)	2005-10-31
ATE428423T1 (de)	2009-05-15
US20090186903A1 (en)	2009-07-23
JP2006501240A (ja)	2006-01-12
RS51903B (sr)	2012-02-29
JP4729306B2 (ja)	2011-07-20
US7115587B2 (en)	2006-10-03
RU2342931C2 (ru)	2009-01-10
AU2003269965B2 (en)	2008-02-21
CN100335047C (zh)	2007-09-05
CN1674882A (zh)	2005-09-28
KR20050040927A (ko)	2005-05-03
PE20040895A1 (es)	2004-11-20
US20110160224A1 (en)	2011-06-30
MXPA05001865A (es)	2005-06-03
US20130045981A1 (en)	2013-02-21
EP1542668A4 (de)	2007-10-17
US7550445B2 (en)	2009-06-23
AU2003269965A1 (en)	2004-03-11
NZ537995A (en)	2007-11-30
US20060234979A1 (en)	2006-10-19
CA2495864C (en)	2011-09-27
RU2005107471A (ru)	2005-09-10
IS2878B (is)	2014-04-15
ZA200501064B (en)	2006-12-27
WO2004017897A2 (en)	2004-03-04
NO20050661L (no)	2005-03-16
NO333458B1 (no)	2013-06-10
CY1110331T1 (el)	2015-01-14
AR040887A1 (es)	2005-04-20
TW200405813A (en)	2004-04-16
US20120053145A1 (en)	2012-03-01

Publication	Publication Date	Title
DE60327225D1 (de)	2009-05-28	Aripiprazol-komplex-formulierung und verfahren
DE60325690D1 (de)	2009-02-26	Halbleiterbauelement und verfahren zu seiner herstellung
DE602005015421D1 (de)	2009-08-27	Direktkomprimierte formulierung und verfahren
DE60212580D1 (de)	2006-08-03	Ortungssystem und Verfahren
DE602004017342D1 (de)	2008-12-04	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
DE50214717D1 (de)	2010-11-25	Und verfahren zu seiner herstellung
DE602004021927D1 (de)	2009-08-20	Halbleiterbauelement und verfahren zu seiner herstellung
DE60337036D1 (de)	2011-06-16	Halbleiterbauelement und verfahren zu seiner herstellung
DE602004015020D1 (de)	2008-08-28	Harzverkapselter elektronischer Bauteil und Verfahren zu seiner Herstellung
DE60317688D1 (de)	2008-01-03	FLüSSIGKEITS-PROBENEHMER UND VERFAHREN
DE60335812D1 (de)	2011-03-03	Biosensor und verfahren zu seiner herstellung
EP1616995A4 (de)	2009-09-23	Nassvlies und verfahren zu seiner herstellung
DE60317772D1 (de)	2008-01-10	Zweirichtungenmischrotor und verfahren
DE60332463D1 (de)	2010-06-17	Hochbrillianter mechanolumineszenzstoff und verfahren zu seiner herstellung
DE60228044D1 (de)	2008-09-18	Verteiltes Rechnersystem und Verfahren
DE60309411D1 (de)	2006-12-14	Pollensensor und Verfahren
DE60239493D1 (de)	2011-04-28	Halbleiterbauelement und verfahren zu seiner herstellung
DE60219261D1 (de)	2007-05-16	Lageranordnung und Verfahren
DE60333155D1 (de)	2010-08-12	Simultandolmetschen- System und Verfahren
EP1599904A4 (de)	2006-04-26	Laterale lubistorstruktur und verfahren
DE60330080D1 (de)	2009-12-31	Pin Halterung und Verfahren
DE60233077D1 (de)	2009-09-03	Halbleiterbauelement und verfahren zu seiner herstellung
EP1455841A4 (de)	2004-12-08	Osteopontin-verwandte zusammensetzungen und verfahren
DE602004027703D1 (de)	2010-07-29	Schwefelfreie zusammensetzung und schmiermittelzusammensetzung und verfahren davon
EP1518959A4 (de)	2009-09-30	Flächengebilde und verfahren zu seiner herstellung

Legal Events

Date	Code	Title	Description
2010-05-06	8364	No opposition during term of opposition